- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Biosimilars Forum Launches State-by-State Savings Calculator
An interactive tool from Biosimilars Forum, an industry group, uses data from Pacific Research Institute to calculate potential biosimilar savings based on 75% market share.
How much could New Jersey save with biosimilars annually? The answer is $294.2 million, if biosimilars achieve a 75% market share, according to an interactive tool developed by Biosimilars Forum using Pacific Research Institute data.
The tool can provide similar savings information for every other state in the union, including Hawaii, California, Arkansas, and Florida ($45.1 million, $1.0 billion, $148.8 million, and $960.6 million, respectively).
In total, the tool predicts annual savings of $14.08 billion annually from biosimilars. The tool bases those savings on biosimilars achieving a 75% market share in each state.
The reality is that actual biosimilar market share is well below that level for many therapeutic and supportive care categories. Only in the filgrastim category is biosimilar share above 75%—the actual share is 78%—according to Amgen’s 2021 Biosimilar Trends Report.
Trastuzumab biosimilars have achieved a 70% share in the United States, relative to the reference product (Herceptin), and bevacizumab biosimilars are close behind with 69%, relative to the originator (Avastin), according to Amgen.
Infliximab, epoetin alfa, and pegfilgrastim biosimilars all have market shares under 40% relative to their originator products.
These hurdles are acknowledged in the Biosimilars Forum interactive tool report. “Misaligned incentives have made these medicines difficult for patients to access and physicians to prescribe. The current provider reimbursement system does not financially encourage the prescribing of lower-cost biosimilars," the report notes.
Sandoz in a recent report estimated US total biosimilar savings of $2.2 billion in 2019. The company was the first to bring a biosimilar to market (Zarxio, filgrastim; 2015). The Sandoz report was in agreement with the Biosimilars Forum in estimating potential 5-year savings of $100 billion from biosimilars.
The Biosimilars Forum called upon Congress and President Joe Biden to “enact commonsense policy changes” that would spur greater use of biosimilars and “unlock these savings.”
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
Resolution of Injection Site Reactions After Switching to Adalimumab Biosimilar
February 22nd 2025A 15-year-old girl with ulcerative colitis who developed injection site reactions to the adalimumab reference product was successfully switched to the biosimilar LBAL without recurrence of symptoms, demonstrating the safety and effectiveness of switching for medical reasons, likely due to an allergic reaction to an excipient in the originator.
